Disclosed purchases by Rep. Ro Khanna and Rep. Lisa McClain rank among the strongest post-filing performers in recent congressional trading data. Ro Khanna bought MRNA with the position disclosed on January 6, 2026. That trade has returned 468.81 percent since disclosure. These returns are measured from the DISCLOSURE date forward and the public could have seen each of these positions when they were filed.
Lisa McClain's CIEN purchase, disclosed August 13, 2025, has gained 333.91 percent since filing. Additional verified outperformers include Tim Moore's TZA buy disclosed July 9, 2025, now at 316.57 percent, and Scott H. Peters' KSS purchase disclosed May 16, 2025, which stands at 280.3 percent. The associated alpha readings range from 238 to 436 points above benchmark, with holding periods between 485 and 651 days.
Two positions qualify as outliers we are still verifying rather than trades with finalized figures. Ro Khanna's CCG buy, disclosed February 6, 2026, currently indicates a return of 840.12 percent. Lisa McClain's SNDK purchase, disclosed November 21, 2025, shows 832.94 percent. Both remain under review and we are not asserting these exact performance levels until verification completes.
The outperformers touch healthcare, technology, consumer cyclical and leveraged small-cap segments, reflecting varied positioning that became visible through standard government filings. Current data offers no guarantee of repetition, yet the pattern of sizable gains after public disclosure supplies concrete numbers for investors reviewing official records from congress.gov and related primary sources. Tracking disclosure dates rather than transaction dates remains essential when evaluating these filings.
This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.